The Institute of Technology on Immunobiologicals (Bio-Manguinhos) is Fiocruz unit responsible for research, innovation, technological development and the production of vaccines, diagnostic kits and biopharmaceuticals primarily aimed at meeting the demands of the Brazilian Public Health System. The Institute's Technological Vaccine Complex, one of the largest production centers in Latin America, installed on Fiocruz campus, guarantees self-sufficiency in essential vaccines for the basic immunization schedule of the Brazilian Ministry of Health.
With 50 years of existence, Bio-Manguinhos has become the largest federal laboratory in Latin America and has established itself as a strategic driver of public health policies in Brazil. To keep up with the trends and best practices in the pharmaceutical industry, the investment in the expansion and modernization of infrastructure is constant, being part of the innovation process of the Institute.
With its own technological development projects and partnerships, in addition to technology transfer agreements with public and private institutions, Bio-Manguinhos provides a range of products for the Brazilian Public Health System (SUS), through the programs of the Ministry of Health. The result is the annual supply of millions of doses of vaccines, IVDs tests, vials and syringes of biopharmaceuticals that expand the population’s access to high-quality products. The Institute also contributes to the public health of several countries, mainly by the export of the yellow fever vaccine, pre-qualified by the World Health Organization (WHO).
For 50 years, we have saved millions of lives. Now, we are transforming global health with cutting-edge platforms, leading Latin America’s advanced therapies.
CAR-T
Bio-Manguinhos CAR-T therapy will be the first 100% produced in Latin America. Based on a point-of-care production model, the initiative will drastically reduce costs and expand the access of this cutting-edge treatment through Brazilian Public Health System.
First public initiative for CAR-T production in Latin America- Partnership with Caring Cross to develop revolutionary CAR-T cell therapy in Brazil
- Local manufacturing aims to reduce costs and expand SUS access
- Bio-Manguinhos holds exclusive technology rights for Latin America
- Targeted at hematological cancers resistant to conventional treatments
- Clinical trials for leukemia and lymphoma conducted through partnership
- Modular unit arrival marks the starting point for local cell production
- Project aligned with national health innovation and sovereignty policies
Science that transforms cells into hope | 
Video
Biosimilars
Bio-Manguinhos has a portfolio of 10 biosimilars for rheumatoid arthritis, psoriasis, Crohn's disease, and different types of cancer, that benefit thousands of patients. Produced from living organisms under highly controlled processes, biosimilars provide the same quality, safety and efficacy at reduced costs.
Biossimilars Safety, Efficacy and Acessibility | Video
mRNA
One of the Covid-19 pandemic's legacies in terms of innovation, Bio-Manguinhos mRNA platform led the Institute to be recognized by the World Health Organization (WHO) as a reference for this type of technology for Latin America. The platform will allow the development of vaccines and advanced therapies.
Fiocruz RNA Platform: Seeding the innovation ecosystem in Latin America | Video
Bio-Manguinhos/Fiocruz: Innovation and Production at the service of Public Health | Video
